• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用热熔挤出技术制备塞来昔布片及应用过程分析技术鉴别增溶效果

Preparation of celecoxib tablet by hot melt extrusion technology and application of process analysis technology to discriminate solubilization effect.

机构信息

College of Pharmacy, Sahmyook University, Seoul, Republic of Korea.

College of Pharmacy, Catholic University of Daegu, Gyeongbuk, Republic of Korea.

出版信息

Pharm Dev Technol. 2020 Jun;25(5):525-534. doi: 10.1080/10837450.2020.1723023. Epub 2020 Feb 3.

DOI:10.1080/10837450.2020.1723023
PMID:31985320
Abstract

The aim of this study was to prepare various types of solid dispersions (SDs) by the hot-melt extrusion technique. Next, process analytical technology (PAT) such as Fourier transform-infrared (FT-IR) and Raman and near infrared (NIR) spectroscopy were applied to determine the solubilization effect. The SDs and its tablets were prepared. Differential scanning calorimetry (DSC), X-ray diffraction (XRD), and scanning electron microscopy (SEM) were performed to determine the morphological and crystalline characteristics of the SDs. Additionally, PAT analyses were performed to identify the solubilization of the celecoxib. Dissolution testing was performed using the paddle method indicated in the US Pharmacopeia Apparatus II. Based on SEM, DSC, and XRD analysis, all SDs changed successfully from the crystalline to the amorphous form. However, FT-IR, Raman, and NIR analysis used in PAT showed that SDs were divided into two groups. New peaks formed as the amount of drug loading increased to >50% in the SD and the dissolution rates were lower than those of the marketed drug. Drug loading levels of ≤50% showed no new peak and exhibited strong solubilization effects. PAT tools can be used to discriminate between extrudates with poor (<50% drug release after 120 min) and desirable (>75% drug release after 120 min) dissolution performance.

摘要

本研究旨在通过热熔挤出技术制备各种类型的固体分散体(SD)。接下来,应用过程分析技术(PAT),如傅里叶变换红外(FT-IR)和拉曼以及近红外(NIR)光谱法来确定增溶效果。制备了 SD 及其片剂。差示扫描量热法(DSC)、X 射线衍射(XRD)和扫描电子显微镜(SEM)用于确定 SD 的形态和结晶特性。此外,还进行了 PAT 分析以鉴定塞来昔布的增溶情况。使用美国药典仪器 II 中规定的桨法进行溶出度测试。基于 SEM、DSC 和 XRD 分析,所有 SD 都成功地从结晶态转变为无定形态。然而,PAT 中使用的 FT-IR、拉曼和 NIR 分析表明,SD 分为两组。随着 SD 中药物负载量增加到>50%,形成了新的峰,且溶出速率低于市售药物。药物负载量≤50%时没有新的峰,表现出较强的增溶效果。PAT 工具可用于区分挤出物的溶出性能较差(120 分钟后药物释放<50%)和理想(120 分钟后药物释放>75%)。

相似文献

1
Preparation of celecoxib tablet by hot melt extrusion technology and application of process analysis technology to discriminate solubilization effect.采用热熔挤出技术制备塞来昔布片及应用过程分析技术鉴别增溶效果
Pharm Dev Technol. 2020 Jun;25(5):525-534. doi: 10.1080/10837450.2020.1723023. Epub 2020 Feb 3.
2
Drug-Smectite Clay Amorphous Solid Dispersions Processed by Hot Melt Extrusion.热熔挤出法制备药物-蒙脱石无定型固体分散体。
AAPS PharmSciTech. 2020 Oct 8;21(7):276. doi: 10.1208/s12249-020-01813-x.
3
Five-Stage Approach for a Systematic Screening and Development of Etravirine Amorphous Solid Dispersions by Hot-Melt Extrusion.五阶段方法通过热熔挤出法对依曲韦林无定形固体分散体进行系统筛选和开发。
Mol Pharm. 2020 Feb 3;17(2):554-568. doi: 10.1021/acs.molpharmaceut.9b00996. Epub 2020 Jan 23.
4
Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.使用喷雾干燥机制备的塞来昔布在PVP/异麦芽酮糖醇固体分散体中的异常溶解行为。
Mater Sci Eng C Mater Biol Appl. 2017 Mar 1;72:501-511. doi: 10.1016/j.msec.2016.11.042. Epub 2016 Nov 14.
5
Preparation of tofacitinib sustained-release tablets using hot melt extrusion technology.采用热熔挤出技术制备托法替尼缓释片。
Pharm Dev Technol. 2024 Mar;29(3):248-257. doi: 10.1080/10837450.2024.2323621. Epub 2024 Mar 4.
6
Influence of Plasdone S630 Ultra-an Improved Copovidone on the Processability and Oxidative Degradation of Quetiapine Fumarate Amorphous Solid Dispersions Prepared via Hot-Melt Extrusion Technique.聚维酮 S630Ultra-一种改良共聚维酮对富马酸喹硫平无定形固体分散体热熔挤出工艺及氧化降解的影响。
AAPS PharmSciTech. 2021 Jun 28;22(5):196. doi: 10.1208/s12249-021-02069-9.
7
Improvement of dissolution and tabletability of carbamazepine solid dispersions with high drug loading prepared by hot-melt extrusion.热熔挤出法制备的高载药量卡马西平固体分散体的溶出度及可压性的改善
Pharmazie. 2019 Sep 1;74(9):523-528. doi: 10.1691/ph.2019.9008.
8
Development of 3D-printed dual-release fixed-dose combination through double-melt extrusion.通过双熔融挤出技术开发 3D 打印双层释放固定剂量复方制剂。
Int J Pharm. 2024 Aug 15;661:124407. doi: 10.1016/j.ijpharm.2024.124407. Epub 2024 Jun 30.
9
3D-printed tablets using a single-step hot-melt pneumatic process for poorly soluble drugs.采用一步热熔气动工艺制备用于难溶性药物的 3D 打印片剂。
Int J Pharm. 2021 Feb 15;595:120257. doi: 10.1016/j.ijpharm.2021.120257. Epub 2021 Jan 22.
10
A Comparative Assessment of Cocrystal and Amorphous Solid Dispersion Printlets Developed by Hot Melt Extrusion Paired Fused Deposition Modeling for Dissolution Enhancement and Stability of Ibuprofen.热熔挤出-熔融沉积成型制备共晶和无定形固体分散体打印片剂提高布洛芬溶出度和稳定性的比较评估
AAPS PharmSciTech. 2023 Oct 2;24(7):203. doi: 10.1208/s12249-023-02666-w.

引用本文的文献

1
Cooling-Triggered Release of Celecoxib from Implantable Alginate-Soluplus Composite Devices.可植入藻酸盐-固体分散体复合装置中塞来昔布的冷却触发释放
ACS Biomater Sci Eng. 2025 Sep 8;11(9):5413-5425. doi: 10.1021/acsbiomaterials.5c00867. Epub 2025 Aug 25.
2
Prodigiosin/celecoxib-loaded into zein/sodium caseinate nanoparticles as a potential therapy for triple negative breast cancer.载有普瑞地辛/塞来昔布的玉米醇溶蛋白/酪蛋白酸钠纳米粒作为治疗三阴性乳腺癌的潜在疗法。
Sci Rep. 2024 Jan 2;14(1):181. doi: 10.1038/s41598-023-50531-4.
3
Investigation of Patient-Centric 3D-Printed Orodispersible Films Containing Amorphous Aripiprazole.
含无定形阿立哌唑的以患者为中心的3D打印口腔崩解膜的研究。
Pharmaceuticals (Basel). 2022 Jul 19;15(7):895. doi: 10.3390/ph15070895.
4
Preparation of Hot-Melt Extruded Dosage Form for Enhancing Drugs Absorption Based on Computational Simulation.基于计算模拟的用于增强药物吸收的热熔挤出剂型制备
Pharmaceutics. 2020 Aug 11;12(8):757. doi: 10.3390/pharmaceutics12080757.
5
Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products.无定形固体分散体:制备、表征、生物利用度机制、稳定性、监管考虑因素和上市产品的更新。
Int J Pharm. 2020 Aug 30;586:119560. doi: 10.1016/j.ijpharm.2020.119560. Epub 2020 Jun 18.